Siyu Chen

Dr. Siyu Chen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CLChien-Hui Lo
Chien-Hui Lo
ZLZhiquan Liu
Zhiquan Liu
SCSiyu Chen
Siyu Chen
FLFrank Lin
Frank Lin
ABAndrew R. Berneshawi
Andrew R. Berneshawi
YSYang Sun
Yang Sun
Mitochondria-related neurodegenerative diseases have been implicated in the disruption of primary cilia function. Mutation in an intrinsic mitochondrial complex I component NDUFAF2 has been identified in Leigh syndrome, a severe inherited mitochondriopathy. Mutations in ARMC9 , which encodes a basal body protein, cause Joubert syndrome, a ciliopathy with defects in the brain, kidney, and eye. Here, we report a mechanistic link between mitochondria metabolism and primary cilia signaling. We discovered that loss of NDUFAF2 caused both mitochondrial and ciliary defects in vitro and in vivo and identified NDUFAF2 as a binding partner for ARMC9. We also found that NDUFAF2 was both necessary and sufficient for cilia formation and that exogenous expression of NDUFAF2 rescued the ciliary and mitochondrial defects observed in cells from patients with known ARMC9 deficiency. NAD + supplementation restored mitochondrial and ciliary dysfunction in ARMC9-deficient cells and zebrafish and ameliorated the ocular motility and motor deficits of a patient with ARMC9 deficiency. The present results provide a compelling mechanistic link, supported by evidence from human studies, between primary cilia and mitochondrial signaling. Importantly, our findings have significant implications for the development of therapeutic approaches targeting ciliopathies.

2 June 2025 in PNAS Nexus
Verified
Journal Article
Open access
SCSiyu Chen
Siyu Chen
ZLZhiquan Liu
Zhiquan Liu
CLChien-Hui Lo
Chien-Hui Lo
QWQing Wang
Qing Wang
KNKe Ning
Ke Ning
YSYang Sun
Yang Sun
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.

20 December 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
ZLZhiquan Liu
Zhiquan Liu
SCSiyu Chen
Siyu Chen
CLChien-Hui Lo
Chien-Hui Lo
QWQing Wang
Qing Wang
YSYang Sun
Yang Sun
Retinitis pigmentosa (RP) is a complex group of inherited retinal diseases characterized by progressive death of photoreceptor cells and eventual blindness. Pde6a , which encodes a cGMP-specific phosphodiesterase, is a crucial pathogenic gene for autosomal recessive RP (RP43); there is no effective therapy for this form of RP. The compact CRISPR/ Staphylococcus aureus Cas9 (CRISPR/SaCas9) system, which can be packaged into a single adeno-associated virus (AAV), holds promise for simplifying effective gene therapy. Here, we demonstrated that all-in-one AAV-SaCas9–mediated Nrl gene inactivation can efficiently prevent retinal degeneration in a RP mouse model with Pde6a nmf363/nmf363 mutation. We screened single-guide RNAs capable of efficiently editing the mouse Nrl gene in N2a cells and then achieved effective gene editing by using a single AAV to codeliver SaCas9 and an optimal Nrl -sg2 into the mouse retina. Excitingly, in vivo inactivation of Nrl improved photoreceptor cell survival and rescued retinal function in treated Pde6a- deficient mice. Thus, we showed that a practical, gene-independent method, AAV-SaCas9–mediated Nrl inactivation, holds promise for future therapeutic applications in patients with RP.

1 April 2024 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
SCSiyu Chen
Siyu Chen
CLChien-Hui Lo
Chien-Hui Lo
ZLZhiquan Liu
Zhiquan Liu
QWQing Wang
Qing Wang
KNKe Ning
Ke Ning
YSYang Sun
Yang Sun
Lowe syndrome, a rare X-linked multisystem disorder presenting with major abnormalities in the eyes, kidneys, and central nervous system, is caused by mutations in OCRL gene (NG_008638.1). Encoding an inositol polyphosphate 5-phosphatase, OCRL catalyzes the hydrolysis of PI(4,5)P2 into PI4P. There are no effective targeted treatments for Lowe syndrome. Here, we demonstrate a novel gene therapy for Lowe syndrome in patient fibroblasts using an adenine base editor (ABE) that can efficiently correct pathogenic point mutations. We show that ABE8e-NG-based correction of a disease-causing mutation in a Lowe patient-derived fibroblast line containing R844X mutation in OCRL gene, restores OCRL expression at mRNA and protein levels. It also restores cellular abnormalities that are hallmarks of OCRL dysfunction, including defects in ciliogenesis, microtubule anchoring, α-actinin distribution, and F-actin network. The study indicates that ABE-mediated gene therapy is a feasible treatment for Lowe syndrome, laying the foundation for therapeutic application of ABE in the currently incurable disease.

9 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SCSiyu Chen
Siyu Chen
ZLZhiquan Liu
Zhiquan Liu
WWWenmin Wang
Wenmin Wang
QWQing Wang
Qing Wang
TKTia J. Kowal
Tia J. Kowal
YSYang Sun
Yang Sun
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5‐phosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutation‐agnostic OCRL DNA augmentation therapy and a patient‐specific CRISPR‐mediated gene correction strategy. The results showed that AAV2‐OCRL demonstrated the highest transduction efficiency in patient iPSC‐derived trabecular meshwork models (iHTM) among the three AAV‐OCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPR‐based gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSC‐derived trabecular meshwork cell models. Furthermore, RNA‐sequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECM‐adhesion‐cytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndrome‐associated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPR‐based gene editing in patient‐derived ocular models and position AAV2‐OCRL as a leading therapeutic candidate for Lowe syndrome.

18 September 2026 in eLife
Verified
Journal Article
Open access
GWGrzegorz Walkiewicz
Grzegorz Walkiewicz
SCSiyu Chen
Siyu Chen
CLChienhui Lo
Chienhui Lo
JZJingyu Zhao
Jingyu Zhao
ZLZhiquan Liu
Zhiquan Liu
YSYang Sun
Yang Sun
Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an Ocrl knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, our findings support a model in which OCRL deficiency is associated with mitochondrial dysfunction, increased oxidative stress, altered neural lineage balance, and reduced Hedgehog pathway activity, providing a framework for understanding these interconnected phenotypes.